RU2017146398A - Экзосомы и их применение в качестве вакцины - Google Patents
Экзосомы и их применение в качестве вакцины Download PDFInfo
- Publication number
- RU2017146398A RU2017146398A RU2017146398A RU2017146398A RU2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- disease
- exosome
- peptide
- animal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 2
- 241001161492 Exosoma Species 0.000 title 1
- 210000001808 exosome Anatomy 0.000 claims 15
- 241001465754 Metazoa Species 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 244000052769 pathogen Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (20)
1. Экзосома, выделенная у животного, (а) которое перенесло заболевание, вызванное патогеном, и (b) у которого отсутствует патоген, который вызывает это заболевание.
2. Экзосома по п.1, где животное перенесло вирусное заболевание и у которого отсутствует вирус, который вызывает это заболевание.
3. Экзосома по п.2, где животное является сельскохозяйственным животным.
4. Экзосома по п.3, где сельскохозяйственное животное является свиньей.
5. Экзосома по любому из пп. 1-4, где заболеванием является вирусное респираторное заболевание.
6. Экзосома по любому из пп. 1-5, где животное представляет собой не зараженную вирусом свинью, которая перенесла респираторное вирусное заболевание.
7. Экзосома по п.6, где животное представляет не зараженную вирусом свинью, которая перенесла респираторное заболевание, вызванное вирусом репродуктивно-респираторного синдрома свиней (PRRSV).
8. Экзосома по любому из пп. 1-7, где везикула содержит пептид, содержащий последовательность, выбранную из группы, состоящей из SEQ ID NO:1 и SEQ ID NO:15, и пептид, который по меньшей мере на 85% идентичен любой из последовательностей SEQ ID NO:1-15.
9. Пептид с длиной последовательности, равной или меньшей 100 аминокислот, и содержащий последовательность, выбранную из группы, состоящей из SEQ ID NO:1-15, и последовательность, которая по меньшей мере на 85% идентична последовательности SEQ ID NO:1-15.
10. Пептид по п.9, который представляет собой одну из последовательностей SEQ ID NO:16, 17, 18 или последовательность, которая по меньшей мере на 85% идентична любой из последовательностей SEQ ID NO:16-18:
11. Способ получения внеклеточных везикул по любому из пп. 1-8, который включает выделение экзосом из тестируемого образца животного, (а) которое перенесло заболевание, вызванное патогеном, и (b) у которого отсутствует патоген, который вызывает это заболевание, как определено в любом из предыдущих пунктов.
12. Способ по п.11, где тестируемым образцом является образец сыворотки.
13. Способ по любому из пп. 11-12, где экзосомы отделяют с помощью эксклюзионной хроматографии.
14. Фармацевтическая или ветеринарная композиция, содержащая внеклеточную везикулу, как определено в любом из пп. 1-8, или пептид по любому из пп. 8-9, и один или несколько фармацевтически или ветеринарно приемлемых эксципиентов или носителей.
15. Фармацевтическая или ветеринарная композиция по п.14, которая является вакциной.
16. Экзосома по любому из пп. 1-8 или пептид по любому из пп. 9-10 для применения в качестве иммуногена.
17. Экзосома по любому из пп. 1-8 или пептид по любому из пп. 9-10 для применения в качестве лекарственного средства.
18. Применение экзосомы по любому из пп. 1-8 или пептида по любому из пп. 9-10 при лечении или профилактики вирусного, бактериального или паразитарного заболевания.
19. Способ идентификации пептида, кандидата в иммуногены, включающий стадию анализа белковой композиции экзосомы по любому из пп. 1-8.
20. Применение экзосомы по любому из пп. 1-8 для проведения различия между животными, вакцинированными везикулой по любому из пп. 1-8, и животными, инфицированными тем же патогеном, как патоген, указанный в п.1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201530775 | 2015-06-03 | ||
| ESP201530775 | 2015-06-03 | ||
| PCT/EP2016/062637 WO2016193422A1 (en) | 2015-06-03 | 2016-06-03 | Exosomes and their use as vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017146398A true RU2017146398A (ru) | 2019-07-10 |
| RU2017146398A3 RU2017146398A3 (ru) | 2019-11-05 |
| RU2763524C2 RU2763524C2 (ru) | 2021-12-30 |
Family
ID=56119476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017146398A RU2763524C2 (ru) | 2015-06-03 | 2016-06-03 | Экзосомы и их применение в качестве вакцины |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11020471B2 (ru) |
| EP (1) | EP3302535A1 (ru) |
| CA (1) | CA2992639A1 (ru) |
| MX (1) | MX2017015279A (ru) |
| RU (1) | RU2763524C2 (ru) |
| WO (1) | WO2016193422A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015279A (es) * | 2015-06-03 | 2018-05-15 | Innovex Therapeutics S L | Exasomas y su uso como vacunas. |
| US20210040447A1 (en) * | 2018-02-26 | 2021-02-11 | Claudia Zylberberg | Immune cell activation |
| EP3837349A4 (en) * | 2018-08-16 | 2022-06-08 | The Regents of the University of California | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLISTER FOR INDUCING CELL VESICLES PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF |
| US20210355492A1 (en) * | 2018-09-21 | 2021-11-18 | City University Of Hong Kong | Cargo loaded extracellular vesicles |
| JP2025063000A (ja) * | 2023-10-03 | 2025-04-15 | 緑茵生技股▲ふん▼有限公司 | ポリペプチド及びそれを血糖のコントロール及び／又は脂肪を減少するのに用いる用途 |
| BE1032025B1 (de) * | 2023-11-27 | 2025-04-30 | Inst Animal Science & Veterinary Medicine Shandong Aas | Anwendung eines aus endothelzellen der schweine-hüftarterien gewonnenen exosoms bei der herstellung eines bakteriellen impfstoffs |
| CN117771348B (zh) * | 2023-11-27 | 2024-09-03 | 山东省农业科学院畜牧兽医研究所 | 猪髋动脉内皮细胞源性外泌体在制备细菌疫苗中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2785543B1 (fr) * | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
| MX2017015279A (es) * | 2015-06-03 | 2018-05-15 | Innovex Therapeutics S L | Exasomas y su uso como vacunas. |
-
2016
- 2016-06-03 MX MX2017015279A patent/MX2017015279A/es unknown
- 2016-06-03 RU RU2017146398A patent/RU2763524C2/ru active
- 2016-06-03 WO PCT/EP2016/062637 patent/WO2016193422A1/en not_active Ceased
- 2016-06-03 CA CA2992639A patent/CA2992639A1/en active Pending
- 2016-06-03 EP EP16728659.0A patent/EP3302535A1/en active Pending
- 2016-06-03 US US15/579,153 patent/US11020471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2763524C2 (ru) | 2021-12-30 |
| US20180161416A1 (en) | 2018-06-14 |
| CA2992639A1 (en) | 2016-12-08 |
| US11020471B2 (en) | 2021-06-01 |
| MX2017015279A (es) | 2018-05-15 |
| EP3302535A1 (en) | 2018-04-11 |
| RU2017146398A3 (ru) | 2019-11-05 |
| WO2016193422A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017146398A (ru) | Экзосомы и их применение в качестве вакцины | |
| Chhabra et al. | Immune responses to virulent and vaccine strains of infectious bronchitis viruses in chickens | |
| Yu et al. | Improved immune responses to a bivalent vaccine of Newcastle disease and avian influenza in chickens by ginseng stem-leaf saponins | |
| Ladman et al. | Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98 | |
| CN110862435A (zh) | 非洲猪瘟ctl表位多肽及其应用 | |
| CN103467571B (zh) | 一种畜禽免疫增强剂法氏囊多肽 | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| Cibulski et al. | Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice | |
| Trapp et al. | Infectious bursal disease virus’ interferences with host immune cells: what do we know? | |
| FI3534939T3 (fi) | Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi | |
| Hammond et al. | A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever | |
| JP2016513956A5 (ru) | ||
| Byadgi et al. | The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum) | |
| Zhu et al. | Evaluation and characteristics of immunological adjuvant activity of purified fraction of Albizia julibrissin saponins | |
| Sarfraz et al. | Immune responses to in ovo vaccine formulations containing inactivated fowl adenovirus 8b with poly [di (sodium carboxylatoethylphenoxy)] phosphazene (PCEP) and avian beta defensin as adjuvants in chickens | |
| Ni et al. | Improved immune response to an attenuated pseudorabies virus vaccine by ginseng stem-leaf saponins (GSLS) in combination with thimerosal (TS) | |
| Snider et al. | The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle | |
| Sadat et al. | Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle | |
| Zhang et al. | Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection | |
| CN109134613B (zh) | 一种促进疫苗免疫反应的法氏囊七肽及其应用 | |
| CN103341164B (zh) | 一种鸡传染性法氏囊病抗原抗体复合物、制剂及制备方法 | |
| Medkour et al. | Canine leishmaniosis and first report of Leishmania infantum in the blood of equids in Kabylia (Algeria) | |
| JP2018512152A (ja) | 鳥類ワクチン | |
| RU2018112060A (ru) | Слитый белок | |
| Chen et al. | Distinct antiviral activities of IFNφ1 and IFNφ4 in zebrafish |